Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.
Groenland SL, van Nuland M, Bergman AM, de Feijter JM, Dezentje VO, Rosing H, Beijnen JH, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: bergman am. Eur J Cancer. 2020 May;130:32-38. doi: 10.1016/j.ejca.2020.02.012. Epub 2020 Mar 13. Eur J Cancer. 2020. PMID: 32172196
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Among authors: bergman am. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS). Badrising SK, et al. Among authors: bergman am. Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20. Oncology. 2016. PMID: 27544669
Impact of age on exposure to oral antiandrogen therapies in clinical practice.
Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH. Crombag MBS, et al. Among authors: bergman am. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2. Prostate Cancer Prostatic Dis. 2019. PMID: 30279580
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP. van Dessel LF, et al. Among authors: bergman am. Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7. Nat Commun. 2019. PMID: 31748536 Free PMC article.
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL, Kuppen MCP, Westgeest HM, van Moorselaar RJA, Mehra N, Coenen JLLM, van Oort IM, de Vos AI, Vervenne WL, van den Bergh ACM, Aben KKH, Somford DM, Bergman AM, Uyl-de Groot CA, Gerritsen WR, van den Eertwegh AJM. Notohardjo JCL, et al. Among authors: bergman am. Eur Urol Focus. 2021 Jul;7(4):788-796. doi: 10.1016/j.euf.2020.03.009. Epub 2020 Apr 30. Eur Urol Focus. 2021. PMID: 32362484
167 results